Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Osiris/Genzyme Put Stem Cells On The Deal Map

This article was originally published in The Pink Sheet Daily

Executive Summary

First-in-class MSC-based therapy Prochymal headed to regulators in 2009 for GvHD.

You may also be interested in...



Osiris Will Focus On Liver GvHD While Sorting Data From Failed Studies

"The idea of giving up and going home is simply not in the cards," CEO Mills says.

Osiris Will Focus On Liver GvHD While Sorting Data From Failed Studies

"The idea of giving up and going home is simply not in the cards," CEO Mills says.

Osiris Hiccup In COPD Barely Registers In Maturing Stem Cell Sector

The rapidly evolving stem cell space may have matured to the level where a single company’s misstep no longer raises questions about the viability of the whole endeavor. At least that seems to be the reaction following Osiris Therapeutics’ recent announcement that its mesenchymal stem cell therapy Prochymal produced mixed results in an interim look at a study of 62 patients with chronic obstructive pulmonary disease.

Related Content

Topics

UsernamePublicRestriction

Register

PS067078

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel